<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334932</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000471769</org_study_id>
    <secondary_id>CPMC-AAAB6443</secondary_id>
    <nct_id>NCT00334932</nct_id>
  </id_info>
  <brief_title>Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma</brief_title>
  <official_title>Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and&#xD;
      melphalan, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by&#xD;
      blocking some of the enzymes needed for cell growth. Giving doxorubicin hydrochloride&#xD;
      liposome and melphalan together with bortezomib may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of doxorubicin&#xD;
      hydrochloride liposome , melphalan, and bortezomib and to see how well they work in treating&#xD;
      patients with relapsed or refractory stage I, stage II, or stage III multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and tolerability of doxorubicin HCl liposome, melphalan, and&#xD;
           bortezomib in patients with relapsed or refractory stage I-III multiple myeloma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall response rate, including complete, near-complete, partial, and&#xD;
           minimal response rate, in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to response, progression-free survival, and overall survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen at the MTD in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I, dose-escalation study followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive doxorubicin HCl liposome IV over 30-60 minutes and melphalan&#xD;
           IV over 30 minutes on day 1 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats&#xD;
           every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome, melphalan, and&#xD;
      bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 3 or 4 of 6 patients experience dose-limiting toxicity&#xD;
      after 2 courses of therapy.&#xD;
&#xD;
        -  Phase II: Patients receive doxorubicin HCl liposome, melphalan, and bortezomib at the&#xD;
           MTD as in phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 32 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing treatment-related ≥ grade 3 hematologic or nonhematologic toxicity or treatment-related death (phase I)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response (phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities by NCI criteria (phase II)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma&#xD;
&#xD;
               -  Stage I, II, or III disease according to Durie-Salmon staging criteria&#xD;
&#xD;
          -  Progressive disease, defined as one of the following:&#xD;
&#xD;
               -  For secretory disease:&#xD;
&#xD;
                    -  A 25% increase in serum M-protein or Bence Jones protein (an absolute&#xD;
                       increase of 0.5 g/dL serum M-protein or ≥ 200 mg/24 hours of urine light&#xD;
                       chain excretion)&#xD;
&#xD;
               -  For nonsecretory disease:&#xD;
&#xD;
                    -  Bone marrow biopsy with &gt; 25% increase in plasma cells or an absolute&#xD;
                       increase of ≥ 10% over prior known level&#xD;
&#xD;
                    -  Development of new or worsening existing lytic bone lesions or soft tissue&#xD;
                       plasmacytomas&#xD;
&#xD;
                    -  Hypercalcemia (i.e., calcium &gt; 11.5 mg/dL)&#xD;
&#xD;
                    -  Relapsed after complete response&#xD;
&#xD;
          -  Must have received ≥ 2 of the following therapeutic regimens for multiple myeloma:&#xD;
&#xD;
               -  Nonmyeloablative transplantation&#xD;
&#xD;
                    -  No significant graft-versus-host disease&#xD;
&#xD;
                    -  At least 30 days since prior immunosuppressive therapy (concurrent&#xD;
                       prednisone allowed provided dose is ≤ 10 mg daily)&#xD;
&#xD;
               -  Mobilization with chemotherapy followed by either single or tandem autologous&#xD;
                  stem cell transplantation (considered 1 prior regimen)&#xD;
&#xD;
               -  Mobilization with chemotherapy followed by autologous and subsequent&#xD;
                  nonmyeloablative allogeneic stem cell transplantation (considered 1 prior&#xD;
                  regimen)&#xD;
&#xD;
               -  Any combination of drugs given concurrently (considered 1 prior regimen)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3 (no colony-stimulating factors)&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm^3 (no transfusion support)&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST ≤ 4 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of allergic reaction to compounds containing boron or mannitol&#xD;
&#xD;
          -  No active uncontrolled viral (including HIV), bacterial, or fungal infection&#xD;
&#xD;
          -  No motor or sensory neuropathy ≥ grade 2&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No severe uncontrolled arrhythmia&#xD;
&#xD;
          -  No acute ischemia by EKG&#xD;
&#xD;
          -  LVEF ≥ 35% by MUGA (MUGA required in patients whose lifetime cumulative doxorubicin&#xD;
             hydrochloride dose &gt; 400 mg/m^2)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No grade III or IV toxicity due to previous antineoplastic therapy (except alopecia)&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior doxorubicin HCl liposome, melphalan, and bortezomib as combination therapy&#xD;
             (single or two-drug combinations of these are allowed)&#xD;
&#xD;
          -  No concurrent corticosteroids (≤ 10 mg prednisone/day or equivalent allowed)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent thalidomide&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent antineoplastic treatment for multiple myeloma, including&#xD;
             clarithromycin&#xD;
&#xD;
          -  No concurrent radiation therapy&#xD;
&#xD;
          -  No concurrent nonsteroidal anti-inflammatory agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajai Chari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UCSF Helen Diller Family Comprehensi</last_name>
      <phone>877-827-3222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Herbert Irving Comprehensive Cancer C</last_name>
      <phone>212-305-8615</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chari A, Kaplan L, Linker C, et al.: Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma. [Abstract] Blood 106 (11): A-5182, 2005 .</citation>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>June 7, 2006</study_first_submitted>
  <study_first_submitted_qc>June 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

